中国医药：全资子公司磷酸奥司他韦胶囊获《药品注册证书》

Core Viewpoint - China National Pharmaceutical Group (China Pharma) announced that its wholly-owned subsidiary, Tianfang Pharmaceutical, received a drug registration certificate from the National Medical Products Administration for Oseltamivir Phosphate Capsules, which are primarily used for the treatment of influenza A and B in adults and children aged one year and older, as well as for the prevention of influenza A and B in adults and adolescents aged 13 years and older [1] Group 1 - The drug registration certificate was issued on December 4 [1] - Oseltamivir Phosphate is indicated for both treatment and prevention of influenza [1] - The approval expands the company's product offerings in the antiviral market [1]